Effects of anandamide on the binding and signaling properties of M 1 muscarinic acetylcholine receptors

Biochemical Pharmacology

Volumn 68, Issue 11, 2004, Pages 2207-2219

  Lanzafame, Alfred A ^a   Guida, Elizabeth ^a   Christopoulos, Arthur ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anandamide; Endocannabinoid; Muscarinic acetylcholine receptor; Non competitive interaction; Phosphoinositide accumulation; Radioligand binding

Indexed keywords

ANANDAMIDE; CHOLINERGIC RECEPTOR; METHYLSCOPOLAMINE; MUSCARINIC M1 RECEPTOR; RADIOLIGAND;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; ISOTHERM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REDUCTION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ANIMALS; ARACHIDONIC ACIDS; BINDING SITES; CELL MEMBRANE; CHO CELLS; CRICETINAE; FEMALE; KINETICS; PHOSPHATIDYLINOSITOLS; POLYUNSATURATED ALKAMIDES; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M1;

EID: 7444223419     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.08.005     Document Type: Article

References (32)

1. R.E. Hampson, and S.A. Deadwyler Role of cannabinoid receptors in memory storage Neurobiol Dis 5 1998 474 482
2. R.E. Hampson, and S.A. Deadwyler Cannabinoids, hippocampal function and memory Life Sci 65 1999 715 723
3. D. Jerusalinsky, E. Kornisiuk, and I. Izquierdo Cholinergic neurotransmission and synaptic plasticity concerning memory processing Neurochem Res 22 1997 507 515
4. C.J. Ladner, and J.M. Lee Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited J. Neuropathol Exp Neurol 57 1998 719 731
5. M. Segal, and J.M. Auerbach Muscarinic receptors involved in hippocampal plasticity Life Sci 60 1997 1085 1091
6. M.P. Caulfield Muscarinic receptors-characterization, coupling and function Pharmacol Ther 58 1993 319 379
7. M.P. Caulfield, and N.J. Birdsall International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors Pharmacol Rev 50 1998 279 290
8. R.G. Pertwee Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development Expert Opin Invest Drugs 9 2000 1553 1571
9. R.G. Pertwee, and R.A. Ross Cannabinoid receptors and their ligands Prostaglandins Leukot Essent Fatty Acids 66 2002 101 121
10. M.A. Friedman Inhibition of arylhydrocarbon hydroxylase induction in BALB/C mouse liver by Δ9-tetrahydrocannabinol Res. Commun. Chem. Pathol Pharmacol. 15 1976 541 552
11. E.F. Domino, and A. Bartolini Effects of various psychotomimetic agents on the EEG and acetylcholine release from the cerebral cortex of brainstem transected cats Neuropharmacology 11 1972 703 713
12. D. Braida, and M. Sala Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats Neuroreport 11 2000 2025 2029
13. J.P. Terranova, J.J. Storme, N. Lafon, A. Perio, M. Rinaldi-Carmona, and G. Le Fur Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716 Psychopharmacology (Berl) 126 1996 165 172
14. V. Di Marzo, C.S. Breivogel, Q. Tao, D.T. Bridgen, R.K. Razdan, and A.M. Zimmer Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain J Neurochem 75 2000 2434 2444
15. P.M. Zygmunt, J. Petersson, D.A. Andersson, H. Chuang, M. Sorgard, and V. Di Marzo Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide Nature 400 1999 452 457
16. V. Di Marzo, L. De Petrocellis, F. Fezza, A. Ligresti, and T. Bisogno Anandamide receptors Prostaglandins Leukot Essent Fatty Acids 66 2002 377 391
17. D. Parolaro, P. Massi, T. Rubino, and E. Monti Endocannabinoids in the immune system and cancer Prostaglandins Leukot Essent Fatty Acids 66 2002 319 332
18. T. Kimura, T. Ohta, K. Watanabe, H. Yoshimura, and I. Yamamoto Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor Biol Pharm Bull 21 1998 224 226
19. F.M. Leweke, A. Giuffrida, U. Wurster, H.M. Emrich, and D. Piomelli Elevated endogenous cannabinoids in schizophrenia Neuroreport 10 1999 1665 1669
20. C.C. Felder, and M. Glass Cannabinoid receptors and their endogenous agonists Annu Rev Pharmacol Toxicol 38 1998 179 200
21. S. Lagalwar, E.Z. Bordayo, K.L. Hoffmann, J.R. Fawcett, and W.H. Frey II Anandamides inhibit binding to the muscarinic acetylcholine receptor J Mol Neurosci 13 1999 55 61
22. A. Christopoulos, and K. Wilson Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors Brain Res 915 2001 70 78
23. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
24. A. Christopoulos Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log Trends Pharmacol Sci 19 1998 351 357
25. A. Christopoulos, and T. Kenakin G protein-coupled receptor allosterism and complexing Pharmacol Rev 54 2002 323 374
26. C.J. Ladner, and J.M. Lee Reduced high-affinity agonist binding at the M1 muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations Exp Neurol 158 1999 451 458
27. B.R. Martin Cellular effects of cannabinoids Pharmacol Rev 38 1986 45 74
28. A.S. Bloom, W.S. Edgemond, and J.C. Moldvan Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes Neurochem Res 22 1997 563 568
29. E. Fride, and V. Di Marzo Endocannabinoids Eur J Pharmacol 359 1998 1 18
30. D. Piomelli, M. Beltramo, A. Giuffrida, and N. Stella Endogenous cannabinoid signaling Neurobiol Dis 5 1998 462 473
31. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, and B.R. Martin Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc Natl Acad Sci USA 98 2001 9371 9376
32. W. Gonsiorek, C. Lunn, X. Fan, S. Narula, D. Lundell, and R.W. Hipkin Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide Mol Pharmacol 57 2000 1045 1050